BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sousa M, Monohan G, Rajagopalan N, Grigorian A, Guglin M. Heart transplantation in cardiac amyloidosis. Heart Fail Rev. 2017;22:317-327. [PMID: 28281017 DOI: 10.1007/s10741-017-9601-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Kristen AV, Kreusser MM, Blum P, Schönland SO, Frankenstein L, Dösch AO, Knop B, Helmschrott M, Schmack B, Ruhparwar A, Hegenbart U, Katus HA, Raake PW. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. The Journal of Heart and Lung Transplantation 2018;37:611-8. [DOI: 10.1016/j.healun.2017.11.015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
2 Halatchev IG, Zheng J, Ou J. Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies. J Thorac Dis 2018;10:2034-45. [PMID: 29707360 DOI: 10.21037/jtd.2018.03.134] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
3 Arai K, Murata D, Verissimo AR, Mukae Y, Itoh M, Nakamura A, Morita S, Nakayama K. Fabrication of scaffold-free tubular cardiac constructs using a Bio-3D printer. PLoS One 2018;13:e0209162. [PMID: 30557409 DOI: 10.1371/journal.pone.0209162] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 13.5] [Reference Citation Analysis]
4 Chiou A, Aman E, Kesarwani M. A case report of an infiltrative cardiomyopathy in everyday practice: a specific cause that cannot be missed in the elderly. Eur Heart J Case Rep 2020;4:1-6. [PMID: 33442642 DOI: 10.1093/ehjcr/ytaa382] [Reference Citation Analysis]
5 Panhwar MS, Al-kindi SG, Tofovic D, Oliveira GH, Ginwalla M. Waitlist Mortality of Patients With Amyloid Cardiomyopathy who Are Listed for Heart Transplantation and Implications for Organ Allocation. Journal of Cardiac Failure 2019;25:767-71. [DOI: 10.1016/j.cardfail.2019.04.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
6 Parikh V, Bhardwaj A, Nair A, Bozkurt B. Update in recent clinical trials in heart failure. Curr Opin Cardiol 2019;34:307-14. [PMID: 31082854 DOI: 10.1097/HCO.0000000000000639] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Di Giovanni B, Gustafson D, Delgado DH. Amyloid transthyretin cardiac amyloidosis: diagnosis and management. Expert Review of Cardiovascular Therapy 2019;17:673-81. [DOI: 10.1080/14779072.2019.1662723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Benson MD, Dasgupta NR, Rao R. Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines. Ther Clin Risk Manag 2020;16:749-58. [PMID: 32884276 DOI: 10.2147/TCRM.S185677] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Barrett CD, Alexander KM, Zhao H, Haddad F, Cheng P, Liao R, Wheeler MT, Liedtke M, Schrier S, Arai S, Weisshaar D, Witteles RM. Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. JACC: Heart Failure 2020;8:461-8. [DOI: 10.1016/j.jchf.2019.12.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
10 Kim EJ, Holmes BB, Huang S, Lugo R, Al Aboud A, Goodman S, Hung RR, Slosky D, Stevenson WG, Michaud GF, John RM. Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator. Europace 2020;22:1216-23. [PMID: 32514579 DOI: 10.1093/europace/euaa094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
11 Milani P, Palladini G, Merlini G. New concepts in the treatment and diagnosis of amyloidosis. Expert Review of Hematology 2018;11:117-27. [DOI: 10.1080/17474086.2018.1424534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
12 Panhwar MS, Al-kindi S, Oliveira GH, Ginwalla M. Successful use of palliative inotrope therapy in end-stage cardiac ATTR amyloidosis. Amyloid 2017;24:246-7. [DOI: 10.1080/13506129.2017.1372412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Kreusser MM, Volz MJ, Knop B, Ehlermann P, Schmack B, Ruhparwar A, Hegenbart U, Schönland SO, Katus HA, Raake PW. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis. Clin Res Cardiol 2020;109:700-13. [PMID: 31630214 DOI: 10.1007/s00392-019-01559-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Bitan G. Disease-modifying therapy for proteinopathies: Can the exception become the rule? Prog Mol Biol Transl Sci 2019;168:277-87. [PMID: 31699321 DOI: 10.1016/bs.pmbts.2019.07.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Guendouz S, Grimbert P, Radu C, Cherqui D, Salloum C, Mongardon N, Maghrebi S, Belhadj K, Le Bras F, Teiger E, Couetil JP, Balan A, Kharoubi M, Bézard M, Oghina S, Bodez D, Hittinger L, Audard V, Planté-Bordeneuve V, De la Taille A, Bergoend E, Frenkel V, Fanen P, Leroy V, Duvoux C, Carmagnat M, Folliguet T, Damy T. Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis. Transplant Direct 2022;8:e1323. [PMID: 35747521 DOI: 10.1097/TXD.0000000000001323] [Reference Citation Analysis]
16 Singh BM, Bohara N, Gautam K, Basnet M, Kc S, Kc B, Raut A, Phudong A, Gautam J. A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Cureus 2021;13:e18221. [PMID: 34703707 DOI: 10.7759/cureus.18221] [Reference Citation Analysis]
17 Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 2019;73:2872-91. [PMID: 31171094 DOI: 10.1016/j.jacc.2019.04.003] [Cited by in Crossref: 188] [Cited by in F6Publishing: 153] [Article Influence: 94.0] [Reference Citation Analysis]
18 Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J. 2018;8:44. [PMID: 29795248 DOI: 10.1038/s41408-018-0080-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 11.5] [Reference Citation Analysis]
19 de Marneffe N, Dulgheru R, Ancion A, Moonen M, Lancellotti P. Cardiac amyloidosis: a review of the literature. Acta Cardiologica. [DOI: 10.1080/00015385.2021.1992990] [Reference Citation Analysis]
20 Strouse C, Briasoulis A, Fonseca R, Jethava Y. Approach to a patient with cardiac amyloidosis. J Geriatr Cardiol 2019;16:567-74. [PMID: 31447895 DOI: 10.11909/j.issn.1671-5411.2019.07.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Burton A, Castaño A, Bruno M, Riley S, Schumacher J, Sultan MB, See Tai S, Judge DP, Patel JK, Kelly JW. Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Drug Des Devel Ther 2021;15:1225-43. [PMID: 33776421 DOI: 10.2147/DDDT.S289772] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Manolis AS, Manolis AA, Manolis TA, Melita H. Cardiac amyloidosis: An underdiagnosed/underappreciated disease. European Journal of Internal Medicine 2019;67:1-13. [DOI: 10.1016/j.ejim.2019.07.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
23 Cruz Rodriguez JB, Tallaj JA. Narrative review of pharmacotherapy for transthyretin cardiac amyloid. Ann Transl Med 2021;9:519. [PMID: 33850916 DOI: 10.21037/atm-20-4636] [Reference Citation Analysis]
24 Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15:387-404. [PMID: 31209302 DOI: 10.1038/s41582-019-0210-4] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 31.0] [Reference Citation Analysis]
25 Hasib Sidiqi M, Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer J 2021;11:90. [PMID: 33993188 DOI: 10.1038/s41408-021-00483-7] [Reference Citation Analysis]
26 Smith A, Balmforth D, Treibel TA, Lall K, Oo A, Ambekar S. Cardiac amyloidosis in non-transplant cardiac surgery. J Card Surg 2021;36:2901-10. [PMID: 33993535 DOI: 10.1111/jocs.15629] [Reference Citation Analysis]
27 Guglin M, Zucker MJ, Borlaug BA, Breen E, Cleveland J, Johnson MR, Panjrath GS, Patel JK, Starling RC, Bozkurt B. Evaluation for Heart Transplantation and LVAD Implantation. Journal of the American College of Cardiology 2020;75:1471-87. [DOI: 10.1016/j.jacc.2020.01.034] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 9.5] [Reference Citation Analysis]
28 Kittleson MM, Cole RM, Patel J, Ramzy D, Passano E, Chang DH, Geft DR, Czer L, Vescio R, Chung J, Kobashigawa JA, Arabia F, Esmailian F, Moriguchi JD. Mechanical circulatory support for cardiac amyloidosis. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13663] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
29 Erbel-Khurtsidze S, Seibel R, Moka D, Brandt-Mainz KTJA, Erbel R, Lichtenberg A. [Cardiac amyloidosis and aortic valve stenosis]. Herz 2021;46:485-96. [PMID: 34487196 DOI: 10.1007/s00059-021-05054-x] [Reference Citation Analysis]
30 Nijst P, Tang WW. Recent advances in the diagnosis and management of amyloid cardiomyopathy. Fac Rev 2021;10:31. [PMID: 33817700 DOI: 10.12703/r/10-31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Chih S, McDonald M, Dipchand A, Kim D, Ducharme A, Kaan A, Abbey S, Toma M, Anderson K, Davey R, Mielniczuk L, Campbell P, Zieroth S, Bourgault C, Badiwala M, Clarke B, Belanger E, Carrier M, Conway J, Doucette K, Giannetti N, Isaac D, MacArthur R, Senechal M. Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care. Can J Cardiol 2020;36:335-56. [PMID: 32145863 DOI: 10.1016/j.cjca.2019.12.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
32 Macedo AVS, Schwartzmann PV, de Gusmão BM, Melo MDT, Coelho-Filho OR. Advances in the Treatment of Cardiac Amyloidosis. Curr Treat Options Oncol 2020;21:36. [PMID: 32328845 DOI: 10.1007/s11864-020-00738-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
33 McGoldrick MT, Etchill EW, Giuliano K, Barbur I, Yenokyan G, Whitman G, Kilic A. Improving contemporary outcomes following heart transplantation for cardiac amyloidosis. J Card Surg 2021. [PMID: 34254364 DOI: 10.1111/jocs.15796] [Reference Citation Analysis]
34 Itzhaki Ben Zadok O, Kornowski R. Cardiac Care of Patients with Cardiac Amyloidosis. Acta Haematol 2020;143:343-51. [PMID: 32408301 DOI: 10.1159/000506919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Ross JC, Hutt DF, Burniston M, Grigore SF, Fontana M, Page J, Hawkins PN, Gilbertson JA, Rowczenio D, Gillmore JD. The role of serial 99mTc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis. Amyloid 2021;:1-12. [PMID: 34704883 DOI: 10.1080/13506129.2021.1991302] [Reference Citation Analysis]
36 Taiwo AA, Alapati L, Movahed A. Cardiac amyloidosis: A case report and review of literature. World J Clin Cases 2019; 7(6): 742-752 [PMID: 30968039 DOI: 10.12998/wjcc.v7.i6.742] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]